HealthCap

Type

Venture Capital

Status

Active

Location

Stockholm, Sweden

Total investments

121

Average round size

30M

Portfolio companies

70

Rounds per year

4.32

Lead investments

11

Follow on index

0.42

Exits

31

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaClinical Trials

Summary

HealthCap is the famous VC, which was founded in 1996. The main department of described VC is located in the Stockholm. The venture was found in Europe in Sweden.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the HealthCap, startups are often financed by HBM Healthcare Investments AG, Alta Partners, Johnson & Johnson Development Corporation. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Industrifonden, Apax Partners. In the next rounds fund is usually obtained by Industrifonden, HBM Healthcare Investments AG, Sofinnova Partners.

Opposing the other organizations, this HealthCap works on 2 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2005. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 3 percentage points more often commits exit comparing to other organizations. When the investment is from HealthCap the average startup value is 5-10 millions dollars. The increased amount of exits for fund were in 2015.

We also calculated 6 valuable employees in our database.

For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Algeta, Pulmonx, Fusion Pharmaceuticals We can highlight the next thriving fund investment areas, such as Manufacturing, Health Care. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 4 of the founder, the chance for it to get the investment is meager.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtech
Geo focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
121
Lead investments
11
Exits
31
Rounds per year
4.32
Follow on index
0.42
Investments by industry
  • Biotechnology (96)
  • Health Care (82)
  • Medical (50)
  • Therapeutics (40)
  • Pharmaceutical (34)
  • Show 26 more
Investments by region
  • United States (51)
  • Sweden (28)
  • Denmark (5)
  • France (9)
  • Ireland (5)
  • Show 7 more
Peak activity year
2005
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
16
Avg. valuation at time of investment
139M
Group Appearance index
0.95
Avg. company exit year
11
Avg. multiplicator
5.39
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
ADCendo 29 May 2024 Biotechnology Early Stage Venture 18M Capital Region of Denmark, Copenhagen, Denmark
Pretzel Therapeutics 12 Sep 2022 Biotechnology, Pharmaceutical, Therapeutics Early Stage Venture 72M United States, Massachusetts, Waltham

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.